NEW YORK (GenomeWeb News) – The Sloan-Kettering Institute, part of the Memorial Sloan-Kettering Cancer Center, has licensed Geneva Bioinformatics’ PhenyxServer protein identification and characterization software, GeneBio said today.
 
Under the agreement, Sloan-Kettering researcher Paul Tempst will use the Phenyx protein identification and characterization software in its Clinical Proteomic Technology Assessment for Cancer group.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.